Scientists say they may be able to develop treatments for children with Down's syndrome after the discovery of earliest developmental changes that lead to the illness.

A team of researchers from Barts and the Royal London have found the earliest developmental changes in embryonic stem cells caused by an extra copy of human chromosome 21 that sets off a chain of genetic changes in the developing embryo which results in the condition

Harvard University scientists have made a set of new stem cell lines that make it possible for researchers to explore 10 different genetic disorders including muscular dystrophy and juvenile diabetes. Researchers hope the new research will help them find new treatments for genetic diseases.

The cells were taken from skin and bone marrow of diseased patients and re-programmed to behave like cells from days-old embryos. The subjects, whose ages ranged from one month to 57-years-old, suffered from a range of conditions from Down Syndrome to Parkinson's disease

Spending a few minutes of treadmill training can help Down syndrome infants walk up to four or five months earlier than with only traditional physical therapy, a new study from the University of Michigan says.

The study, available online in advance of publication in Physical Therapy, suggests high intensity training may help Down syndrome infants begin walking five months sooner than they typically do. High intensity training includes increasing the treadmill belt speed, using longer durations, and adding light weights to the ankles, with intensity tailored to each child

Starting Down Syndrome infants walking on a treadmill just few minutes a day can help them walk four to five months earlier than traditional therapies, according to a new study.

Researchers at University of Michigan's Division of Kinesiology asked parents of 30 Down syndrome babies to help them walk on a treadmill for eight minutes a day, five days a week

Scientists have developed a new blood test for the detection of Down's syndrome in pregnant women that can help detect the chromosomal abnormality without the risk of miscarriage. Earlier, the woman's amniotic sac was involved in the test for examining fetal DNA and there was a risk of miscarriage.

The new diagnostic tool developed by the U.S. company Ravgen is very safe than the earlier tests and poses no threat to the mother or fetus. The test uses fetal DNA extracted from mother's blood samples to screen for chromosomal abnormalities